Figure 8.
PDGFRβ promotes GSC in vivo tumor propagation. (A) The median survival and number of tumors formed are shown for 08-387 and 08-322 GSCs expressing nontargeting shRNA (shNT) or shRNA directed against PDGFRβ (shPDGFRβ I and shPDGFRβ II). Kaplan-Meier survival curves for 08-387 (B) and 08-322 (C) GSCs expressing nontargeting shRNA (shNT) or shPDGFRβ demonstrate delayed tumor growth with shPDGFRβ.